Free Trial
NASDAQ:NEUP

Neuphoria Therapeutics Inc. - Common Stock (NEUP) Stock Price, News & Analysis

Neuphoria Therapeutics Inc. - Common Stock logo
$5.05 +0.05 (+1.00%)
As of 05/2/2025 03:24 PM Eastern

About Neuphoria Therapeutics Inc. - Common Stock Stock (NASDAQ:NEUP)

Key Stats

Today's Range
$4.93
$5.25
50-Day Range
$4.64
$5.80
52-Week Range
$2.12
$15.24
Volume
9,423 shs
Average Volume
416,957 shs
Market Capitalization
$8.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Receive NEUP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuphoria Therapeutics Inc. - Common Stock and its competitors with MarketBeat's FREE daily newsletter.

NEUP Stock News Headlines

Neuphoria Therapeutics provides review of 2024, highlights 2025 plans
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More Headlines

NEUP Stock Analysis - Frequently Asked Questions

Neuphoria Therapeutics Inc. - Common Stock's stock was trading at $3.20 at the beginning of the year. Since then, NEUP stock has increased by 57.8% and is now trading at $5.05.
View the best growth stocks for 2025 here
.

Neuphoria Therapeutics Inc. - Common Stock (NASDAQ:NEUP) issued its earnings results on Friday, February, 14th. The company reported ($1.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.01) by $0.78. The firm had revenue of $660 billion for the quarter.

Neuphoria Therapeutics Inc. - Common Stock's top institutional investors include Cyndeo Wealth Partners LLC (0.57%).

Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
2/14/2025
Today
5/03/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NEUP
Previous Symbol
NASDAQ:NEUP
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+315.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$662,715.00
Price / Cash Flow
N/A
Book Value
$7.82 per share
Price / Book
0.65

Miscellaneous

Free Float
1,745,000
Market Cap
$8.87 million
Optionable
N/A
Beta
0.25
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NEUP) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners